EpiAxis Therapeutics is pleased to announce the nomination of epiresatide as its lead candidate for IND advancement.

Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action.

Designed to address the challenge of treatment resistance and prevention of cancer recurrence in numerous haematological and solid tumours, epiresatide has demonstrated superior biological performance in modulating LSD1 demethylase activities, coupled with an excellent pre-clinical safety and tolerability profile.

EpiAxis CEO Dr Jeremy Chrisp said the company is planning to move forward with the clinical development of its lead candidate, epiresatide, marking a significant milestone in its progress,

“This is a pivotal valuation inflection point for shareholders and provides momentum for EpiAxis’ fundraising and partnering activities,” Dr Chrisp said.

“Currently, EpiAxis is actively seeking collaborations and investment opportunities to accelerate the development and commercialisation of epiresatide, cementing its position at the forefront of the biotechnology industry.”

EpiAxis remains dedicated to transforming the lives of cancer patients and meeting the urgent need for more effective treatments. Future updates will be provided on the progress of epiresatide as the company progresses this ground-breaking therapeutic.

For media inquiries, please contact:

Dr Jeremy Chrisp

Phone: +61 421 012 268

EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing – and often toxic – treatments by reprogramming the cancer cells back towards normal cells.